Secondary Logo

Editorial Board

Johannes Vieweg
University of Florida
Florida, USA
Shahrokh F Shariat
Medical University of Vienna
Vienna, Austria

Editorial Board
DM Albala
Associated Medical Professionals,
Syracuse, USA

TJ Bivalacqua
Johns Hopkins Medical Institute,
Baltimore, USA

CR Chapple
Royal Hampshire Hospital,
Sheffield, UK

TK Choueiri
Dana-Farber Cancer Institute, Harvard Medical School,
Boston, USA

L Coetzee
Urology Hospital in Pretoria,
South Africa

P Dahm
University of Minnesota,
Minneapolis, USA

S Daneshmand
University of Southern California,

DA Diamond
Boston Children's Hospital, Harvard Medical School
Boston, USA

A Heidenreich
University Hosital Cologne,

BA Inman
Duke University School of Medicine,
Durham, USA

S Joniau
University Hospitals Leuven,

AS Kibel
Brigham and Women's Hospital, Harvard Medical School,
Boston, USA

E Liatsikos
University Hospital of Petras,

MS Litwin
David Geffen School of Medicine at UCLA,

D Murphy
Peter MacCallum Cancer Centre,
Melbourne, Australia

A Necchi
Fondazione IRCCS Instituto Nazionale dei Tumori,
Milan, Italy

VW Nitti
NYU Langone Medical Center,
New York, USA

G Palapattu
University of Michigan,
Ann Arbour, USA

QD Trinh
Brigham and Women's Hospital, Harvard Medical School,
Boston, USA

Editorial Board Disclosures

​DM Albala
Stock Interest:  Applied Medical
Advisory Board:  Cellanyx
Speaker:  Genomic Health; Myriad

​Trinity Bivalacqua
Grants: NIH R01, K08, R03; BCAN Innovations Award; Greenberg Bladder Cancer Institute
Speaker and Consultant: Photocure
Clinical Trials Principal Investigator: FKD; Photocure; NCI; Tissuegenesis; Heat Biologics; Taris

CR Chapple
Grant, Scientific Study/Trial, Meeting Participant/Lecturer, Consultant/Advisor: Astellas
Consultant/Advisor: GSK
Meeting Participant/Lecturer: Pfizer

Tony Choueiri
Consulting or Advisory Role: AstraZeneca; Bayer; BMS; Cerulean; Eisai; Foundation Medicine Inc.; Exelixis; Genentech; Roche; GlaxoSmithKline; Merck; Novartis; Peloton; Pfizer; Prometheus Labs; Corvus; Ipsen
Research Funding: AstraZeneca; BMS; Exelixis; Genentech; GSK; Merck; Novartis; Peloton; Pfizer; Roche; Tracon; Eisai

L Coetzee

P Dahm
Consultant: Eisai Pharmaceuticals; Array BioPharma
Expert Witness: Bennett Bodine & Waters
Unpaid: Evidence Foundation; US GRADE Network; Society of Academic Urology (SAU)
Editorial: BJU International; World Journal of Urology; Current Opinion in Urology;Cochrane Urology

Sia Daneshmand
Photocure (current, scientific advisory board/consultant/funded study/registry)
Pacific Edge (current, consultant/speaker)
Merck (current, consultant/speaker)
Taris (current, scientific advisory board/consultant/funded study)
Endo Pharmaceutical (past, scientific advisory board/consultant/speaker)

David Diamond

Axel Heidenreich
Honoraria: Amgen; Astellas; Bayer; Dendreon; Ferring; IPSEN; Jansen; Pfizer; Sanofi; Takeda
Advisory Board: Astellas; Bayer; Jansen; Sanofi
Grants: AMGEN; Astellas; Sanofi

Brant Inman
Consultant or Advisor: Combat Medical; BioCancell; Taris Biomedical; AstraZeneca
Scientific Study or Trial: Urogen; Abbott Laboratories; Combat Medical; Nucleix; FKD Therapies; Dendreon; Genentech Inc

Steven Joniau
Consultant: Astellas; Ipsen; Bayer; Sanofi; Janssen
Speaker Honorarium: Astellas; Amgen; Bayer; Sanofi; Janssen; Ipsen
Trial Participation: Astellas; Bayer; Janssen
Travel Grant: Astellas; Amgen; Bayer; Sanofi; Janssen; Ipsen; Pfizer
Research Grant: Astellas; Bayer; Janssen

Adam Kibel
Sanofi -Aventis; GenomeDx; Genomic Health; Dendreon; Tokai; Bayer; Janssen; Profound; MTG; ConfirmMDx

Evangelos Liatsikos
Consultant: COOK Medical
Speaker: Boston Scientific; Karl Storz

MS Litwin

D Murphy
Financial (including grants and donations): Victorian Cancer Agency; NH&MRC; New Technology Program from Department of Health & Ageing in Victoria; Cancer Australia; Beyond Blue
Consultancies and Advisory Boards: Ferring Pharmaceuticals International; Ipsen Pharma International; Janssen Pharmaceuticals International; Astellas International; Bayer; Dendreon; Minomic Ltd
Paid Speaker: Astra Zeneca; Sanofi; Amgen; Hospira; Bayer; CSL; GSK Pharma; Abbott Pharmaceuticals
Travel Support: Intuitive Surgical; Device Technologies Australia
Editorial: BJUI; European Urology; Asian J Urology; Nature Reviews Urology; Prostate Cancer & Prostatic Diseases; Asian Journal of Urology; Ninerva Urologie e Nefrologie

Andrea Necchi
Consulting or Advisory Role: Roche; Bayer; Merck & Co. Inc.; Astra Zeneca; Pfizer; Astellas/Seattle Genetics; Clovis Oncology
Travel, Accommodations, Expenses: Roche; Merck & Co. Inc.; Pierre Fabre; PeerVoice
Research Funding (Institution): Merck & Co. Inc.; Astra Zeneca; Amgen

VW Nitti
Chair of Education: American Urological Association
Investigator: Medtronics; Allergan; Astellas

Ganesh Palapattu
Leadership Role and Equity Interest (Non-Public): Semper Therapeutics LLC
Sponsored Research: Minomic International Ltd
Equity Interest (Public) and Sponsored Research: NantKwest
Expert Witness: Dupont; Takeda Pharmaceuticals
Meeting Travel and Speaker: Astellas
Consultant: Bristol Meyers Squibb; Tokai Pharmaceuticals; Genome Dx

Quoc-Dien Trinh
Conflicts of Interest: Astellas; Bayer​



Male lower urinary tract symptoms
Edited by Oliver Reich,
Klinikum Munich-Harlaching,
Ludwig-Maximilians-University Teaching-Hospital,
Munich, Germany

Genetic testing or biomarkers for the detection of prostate cancer
Edited byDaniel Lin,
University of Washington,
Washington, USA

Organ sparing surgery in urology
Edited by Inderbir Gill,
Keck School of Medicine, University of Southern California,
California, USA

Training in endourology
Edited by Mahesh Desai,
Muljibhai Patel Urological Hospital,
Nadiad, India

Focal therapy of prostate cancer
Edited by Thomas J. Polascik, Duke Cancer Institute,
North Carolina, USA

Active surveillance for favorable risk prostate cancer
Edited by H. Ballentine Carter, John Hopkins School of Medicine, br>Maryland, USA

Advances in Female Urology

Edited by Christopher Chapple,Sheffield Teaching Hospitals NHS Foundation Trust/University of Sheffield, Sheffield, UK

Reconstructive urology
Edited by Margit Fisch,
University of Hamburg, Hamburg, Germany

The future of kidney cancer: quo vadis
Edited by Vitaly Margulis, UT Southwestern Medical Center, Texas, USA
and Manuela Schmidinger, Medical University of Vienna, Vienna, Austria

Personalized medicine in the management of invasive Bladder cancer
Edited by Maximilian Burger, Caritas-St. Josef Medical Centre, University of Regensburg, Regensburg, Germany
and Andrea B. Apolo, National Cancer Institute, Maryland, USA

Imaging in prostate cancer: implications for the urologist
Edited by Mark Emberton,
University College London, London, UK

Urinary diversion 2015: Controversies and new technologies
Edited by Sia Daneshmand,
University of Southern California, California, USA